Key Takeaways
- Domestic formulations surged 27%, but exports stalled: The branded domestic business delivered exceptional growth on broad-based therapy demand, while export formulations grew just 3% as geopolitical disruption halted CIS shipments late in the quarter.
- Margins absorbed a triple hit: An impairment provision of ~₹22.5 cr, elevated freight and fuel costs, and sharply higher field-force incentives compressed Q4 profitability, with full-year value addition slipping to 68% from 70%.
- The UK generics reset is deep and ongoing: Revenue collapsed from ₹60 cr to ₹20 cr in Q4 as the company cut distributor shipments to build its own-label distribution army, with only 7 of 43 products commercialized so far.
- Sartan impurity fallout lingers: Sales returns exceeding ₹20 cr hit the quarter, some more returns are expected in Q1 FY23, and regaining lost market share will take time even though the process fix is filed.
- What to watch next quarter: Whether domestic formulation growth normalizes toward the guided 12–13% as the high base from the Delta wave kicks in, the pace of UK own-label commercialization, and any further Sartan-related sales returns.
Domestic Formulations: The Quarter’s Engine
- Broad-based therapy outperformance: Pain grew 32%, Antibacterials 55%, Antimalarials 64%, and Cough & Cold 72% for the full year, with COVID-19 spread and broad-based treatment patterns lifting acute therapies.
- Field force expansion is aggressive and costly: ~500 marketing people were added in Q4 alone, with 4 new marketing divisions launched from April FY23, taking the medical rep count from 4,800 toward ~6,000. Incentive provisions more than doubled because 27% growth far exceeded the 16% budget.
- The base effect looms: A 2-year CAGR of ~14–15% benefited from a low prior-year base, and Q1 FY23 growth may be lower because April–May FY22 saw elevated offtake from the Delta variant.
- Price increases provide a partial offset: A ~10.7% Aniline price increase was secured, effective from June, and management expects ~8% average non-Aniline price increases in FY23 versus the historical ~6%, driven by wholesale price inflation.
Export Formulations: Geopolitics and a UK Reset
- CIS disruption was the drag: Branded promotional exports grew only 3% because shipments to the CIS region could not be made in end-February and March due to geopolitical issues; excluding that, the promotional market would have grown ~20%.
- Russia outlook has brightened: Shipments normalized from May, the Ruble stabilized at ~57 versus pricing based on 70, and local prices were revised upward based on a 70–90 Ruble rate and not reduced. Management expects dollar billings to improve and sees opportunity as some MNCs have withdrawn.
- Ukraine is a small but disrupted business: Annual business of ~₹15 cr faces logistics difficulties; some shipments sent in early February did not reach their destination.
- The UK generics model is being rebuilt from scratch: Revenue collapsed from ~₹350 cr in FY18-19 to ~₹84 cr in FY22 as the company stopped shipping to distributors and shifted to its own-label distribution army. Only 7 of 43 products have received commercialization approvals, with 6–7 more recently approved and expected to commercialize in Q2.
- UK breakeven is a hope, not a forecast: With the current 13-product basket, management expects ~₹60–65 cr in business; more approvals during the year could improve that and potentially reach breakeven.
A. K. Jain: "In fact, we are sensing that business would definitely go up there. There are good opportunities, our team is working, the team is right now setting from India there to assess all those kind of things which are other dossiers, which are other markets on which we can get Russian approvals..."
API Business: Impurity Fallout and Price Uncertainty
- The Azido impurity issue cut deep: Export API declined 14% to ~₹181 cr in Q4, and overall API declined 15% for FY22, because of the impurity issue in certain APIs and associated sales returns received during the quarter. The issue has since been resolved.
- Sartan returns are not fully behind: Sales returns exceeded ₹20 cr in Q4 as earlier shipments to certain geographies were returned; some more returns may come in Q1 FY23. The business was disturbed for 6–8 months and some market share is likely lost.
- Losartan recovery will be slow: The company has not serviced customers for 4–5 months due to the impurity problem and is regaining business slowly. Some return of older shipments is expected this quarter, replaced with fresh material, causing lower reported growth.
- Intermediate prices are softening, but hesitancy is high: Key intermediate prices that had risen 100–200% have started coming down ~5–10%, but buyers are hesitant to accept higher prices and sellers face volume pressure. Solvent prices remain high due to petroleum.
- Inventory is elevated by design: Inventory rose ~₹200 cr as the company prioritized business continuity and supply security amid China supply uncertainties, even though lower realizations are a risk if raw material prices correct.
A. K. Jain: "Let us say, issue got resolved, we have filed the newer process, whatever with modifications and all, but lot of shipments which were made earlier to certain geographies, they have return back, so sales return was higher."
Harish Kamath: "Yes, that is correct, but whatever benefit we have costing and other things, we are sure we will get back all our customers and all our volume, but it will a slow progress..."
Margins: Cost Pressures and a Provision
- The impairment provision was material: Q4 EBITDA was impacted by an impairment provision of ~₹22.46 cr, with the full-year provision at ~₹39.14 cr.
- Freight and fuel costs surged: Freight cost rose from ₹13.7 cr to ~₹23–24 cr in Q4, fuel cost was up ~60% YoY, and coal prices rose ~120%. Electricity tariff hikes may add further pressure.
- Field-force costs are structurally higher: Personal cost reflects an 8% general increment plus incentive provisions that more than doubled, adding ~₹60 cr, because outperformance triggers significantly higher payouts. New reps typically break even in 2 years and contribute to margin from the third year.
- Gross margin restoration depends on input prices: Value addition fell to 68% from 70%, partly because FY21 was exceptional due to high-margin COVID-related Hydroxychloroquine/Chloroquine business. Management sees no further reduction and expects restoration if intermediate price softening continues.
A. K. Jain: "We are seeing the softening of the prices of certain, the key intermediates in the recent time and probably that trend would continue. So, if that trend continues, then overall our gross margin will further restore."
Capital Projects: Dewas, Ratlam, and the Lyka Journey
- Dewas is a FY24 story with near-term costs: Commercial production started for one intermediate, a second starts next quarter, and the major plant is delayed by 2 months with completion expected July/August. From August to March, ~₹1.5 cr/month in costs will flow through with little revenue recovery, as only lower-priced business is possible without regulatory approvals.
- Ratlam debottlenecking is complete: Commercial production has already started.
- Ramdev API-to-intermediate conversion is progressing: 5–6 products have been validated, filings have started with EDQM and other authorities, and 8–9 filings are expected in the current year. European and other business will start once approvals come through.
- Aurangabad has a bottleneck: The pilot plant is installed and a few stages are stabilized with yields up ~20%, but material-of-construction issues with phosphorous oxychloride stages remain unresolved.
- Lyka injectables is a 2-year journey: The plant has WHO GMP and certain authority approvals but no stringent authority approvals. Modifications are required, quality systems are being assessed, and filings will start first in ROW markets, then stringent markets.
A. K. Jain: "We don't foresee any kind of significant impact of Dewas coming in the current financial year. Dewas will start impacting our overall performance, may be from the second quarter of the next financial year. Nothing great would come, in fact it will contribute the initial losses..."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Domestic formulation growth | ~12–13% for the full year; Q1 may be lower due to high base from Delta wave | FY23 |
| Institutional business | Flat; not much growth expected | FY23 |
| Overall topline growth | 10–12% | FY23 |
| EBITDA margin | 22–22.5%, pressured by additional people, elevated fuel/shipping/inflation costs | FY23 |
| Gross margin | ~68%; may improve if intermediate prices continue softening | FY23 |
| API business growth | ~10% in FY23; ~15% for next 3 years once Dewas capacity available and regulatory inspections done | FY23 / 3 years |
| Branded formulation export growth | ~20% | FY23 |
| UK generics revenue | ~₹60–65 cr from current 13-product basket; could improve with more approvals | FY23 |
| Tax rate | ~25% | FY23 only |
| Sartan sales returns | Some more may come | Q1 FY23 |
| Dewas plant capitalization | Major part ready | August FY23 |
| Dewas plant impact | No significant impact; will start impacting from Q2 FY24, contributing initial losses in the meantime | FY23 / FY24 |
| Lyka injectables stringent-market filings | ~2-year journey: modifications, quality system assessment, filings first in ROW then stringent markets | ~2 years |
Key Metrics
| Metric | Q4 FY22 |
|---|---|
| Domestic formulation revenue | ₹551 cr, +27% YoY from ₹433 cr |
| Export formulation revenue | ₹346 cr, +3% YoY from ₹338 cr |
| Overall API revenue | ₹258 cr, -15% YoY from ₹260 cr |
| Gross margin (value addition) | 70%, vs 72% in Q4 FY21 |
| Full-year gross margin | 68%, vs 70% in FY21 |
| Impairment provision on investments | ₹22.46 cr provided in the quarter |
| Domestic formulation growth outlook FY23 | 12–13% |
| Overall topline growth guidance FY23 | 10–12% |
| EBITDA margin guidance FY23 | 22–22.5% |
| Branded formulation exports growth expectation FY23 | ~20% |
| API business growth outlook FY23 | 10–12% |
| Generic business growth outlook FY23 | ~5% |
| Captive API integration level | ~56% of turnover |
| Field force size | 4,800 medical reps, increasing to ~6,000 in FY23 |
| Cash in balance sheet | ~₹1,300 cr |